SCHEMBL3778065

SCHEMBL3778065

CN1CC2C(CNCc3cccc(CC(F)(F)F)c3)C2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CARM1 Q86X55 4/20 0.36
PRMT6 Q96LA8 4/20 0.36
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
SLC6A9 P48067 1/20 0.33
KCNH2 Q12809 1/20 0.33
CXCR4 P61073 7/20 0.33
UTS2R Q9UKP6 1/20 0.31
OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777124 0.85 CARM1 (0.51) CARM1PRMT6TEAD1
SCHEMBL3783236 0.82 ATM (0.37) ATML3MBTL1CXCR4ENPP2
SCHEMBL3775184 0.81 CARM1 (0.54) ATMCARM1PRMT6SLC6A9KCNH2
SCHEMBL3770032 0.81 CARM1 (0.34) ATML3MBTL1CARM1PRMT6HDAC3
SCHEMBL3770111 0.80 CXCR4 (0.49) CARM1PRMT6SLC6A9CXCR4
SCHEMBL3772620 0.78 CARM1 (0.47) ATMCARM1PRMT6TEAD1
SCHEMBL3778064 0.77 CACNA1H (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3773434 0.76 P2RX7 (0.48) SLC6A9KCNH2ENPP2
SCHEMBL15966985 0.75 CARM1 (0.49) ATMCARM1PRMT6SLC6A9KCNH2
SCHEMBL710582 0.73 CARM1 (0.45) CARM1PRMT6CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 ATM 4469/4885L3MBTL1 1700/4885CARM1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.